Group 1 - The core product of Weisheng Pharmaceutical-B, Longpei Growth Hormone, is expected to be approved soon, having completed its supplementary data task on January 12, 2026 [1] - Longpei Growth Hormone is the first long-acting growth hormone prodrug approved for use in children with Growth Hormone Deficiency (GHD) in the US and Europe, which could significantly enhance patient compliance compared to daily formulations [1][2] - The stock of Weisheng Pharmaceutical-B has risen over 16% this year, outperforming the Hang Seng Index, which has increased by over 4% during the same period [1] Group 2 - Longpei Growth Hormone, introduced by Weisheng Pharmaceutical from Ascendis Pharma, utilizes TransCon technology for long-acting delivery, showing superior efficacy and equivalent safety compared to short-acting growth hormones [2] - The drug has completed critical Phase III trials in China, demonstrating its effectiveness in comparison to short-acting growth hormones [2]
维昇药业-B大涨10% 股价创逾一个月新高 隆培促生长素上市在即
Ge Long Hui·2026-01-23 08:01